U.S. Court of Appeals for the Eleventh Circuit, 2023

Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA

Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA
U.S. Court of Appeals for the Eleventh Circuit · Decided November 9, 2023

Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA

Opinion

USCA11 Case: 23-11047 Document: 28-1 Date Filed: 11/09/2023 Page: 1 of 2

[DO NOT PUBLISH] In the United States Court of Appeals For the Eleventh Circuit ____________________ No. 23-11047 Non-Argument Calendar ____________________ IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION.

9:20-md-02924-RLR ___________________________________________________ ERIK ROY HILLESLAND, CHANMEIKA HILL, Interested Parties-Appellants, versus GLENMARK PHARMACEUTICALS, INC. USA, MARLENE GOLDENBERG, APOTEX CORP., MICHAEL MCCANDLESS, USCA11 Case: 23-11047 Document: 28-1 Date Filed: 11/09/2023 Page: 2 of 2

2 Opinion of the Court 23-11047 BRAD ALDRIDGE, et al.,

Defendants-Appellees.

____________________ Appeal from the United States District Court for the Southern District of Florida D.C. Docket No. 9:20-md-02924-RLR ____________________ Before WILSON, JILL PRYOR, and GRANT, Circuit Judges.

PER CURIAM: Upon review of the record and the response to the jurisdic- tional questions, this appeal is DISMISSED for lack of jurisdiction.

Appellant lacks standing to bring this appeal because there is no evidence that he is, or ever was, a plaintiff in this action, and there is no indication that the district court has ever entered an appeala- ble order that caused him injury. See Wolff v. Cash 4 Titles, 351 F.3d 1348, 1353-54 (11th Cir. 2003); Mickles on behalf of herself v. Country Club, Inc., 887 F.3d 1270, 1278 (11th Cir. 2018).

Case-law data current through December 31, 2025. Source: CourtListener bulk data.